HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.44 USD
-0.12 (-2.63%)
Updated Sep 24, 2024 03:59 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for HOOKIPA Pharma Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 14 | 18 | 20 | 12 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 20 | 14 | 18 | 20 | 12 |
Selling & Adminstrative & Depr. & Amort Expenses | 118 | 87 | 100 | 73 | 63 |
Income After Depreciation & Amortization | -98 | -73 | -82 | -53 | -51 |
Non-Operating Income | 17 | 9 | 7 | 10 | 9 |
Interest Expense | 0 | 1 | 1 | 1 | 1 |
Pretax Income | -81 | -65 | -76 | -44 | -43 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -82 | -65 | -76 | -44 | -43 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -82 | -65 | -76 | -44 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -94 | -70 | -77 | -49 | -50 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 5 | 4 | 1 |
Income After Depreciation & Amortization | -98 | -73 | -82 | -53 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 9.49 | 6.56 | 3.29 | 2.61 | 1.79 |
Diluted EPS Before Non-Recurring Items | -7.50 | -9.90 | -23.00 | -16.90 | -24.10 |
Diluted Net EPS (GAAP) | -8.60 | -9.90 | -23.00 | -16.90 | -24.10 |
Fiscal Year end for HOOKIPA Pharma Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.29 | 36.60 | 7.41 | 6.87 | 2.68 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.29 | 36.60 | 7.41 | 6.87 | 2.68 |
SG&A, R&D, and Dept/Amort Expenses | 23.75 | 25.50 | 25.53 | 29.54 | 24.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.46 | 11.10 | -18.12 | -22.67 | -21.48 |
Non-Operating Income | 3.36 | 3.28 | 6.29 | 3.65 | 3.55 |
Interest Expense | 0.00 | 0.00 | 0.05 | 0.05 | 0.10 |
Pretax Income | -19.10 | 14.38 | -24.66 | -19.07 | -18.02 |
Income Taxes | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -19.10 | 14.38 | -24.82 | -19.07 | -18.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -19.10 | 14.38 | -24.82 | -19.07 | -18.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 12.56 | 13.08 | 11.28 | 11.22 | 8.19 |
Diluted EPS Before Non-Recurring Items | -1.52 | 1.20 | -1.10 | -1.70 | -2.20 |
Diluted Net EPS (GAAP) | -1.52 | 1.10 | -2.00 | -1.70 | -2.20 |